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Abstract Clinical outcomes of migraine treatment are
generally based on two major endpoints: acute pain res-
olution and effects on quality of life (QOL). Resolution of
acute pain can be evaluated in a number of ways, each
increasingly challenging to achieve; pain relief, pain
freedom at 2 h, sustained pain-freedom, and SPF plus no
adverse events (SNAE, the most challenging). QOL
questionnaires help assess the burden of migraine and
identify optimal treatments. Pain resolution and improved
QOL form the basis of the ultimate target—meeting
patient expectations, to achieve patient satisfaction. To
achieve this, it is crucial to choose appropriate endpoints
that reflect realistic treatment goals for individual patients.
Moreover, SNAE can help discriminate between triptans,
with almotriptan having the highest SNAE score. Kaplan–
Meier plots are also relevant when evaluating migraine
treatments. The use of symptomatic medication may lead
to the paradoxical development of medication-overuse
headache. In general practice, patients should use simple
tools for pain measurement (e.g. headache diary) and a
QOL questionnaire. A composite endpoint of pain reso-
lution and QOL restoration would constitute a step
forward in migraine management.
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Introduction
Migraine, other primary headaches, and chronic headache
from overuse of medication have a major impact on suf-
ferers and on society because of their high prevalence in
both young people and adults and their negative conse-
quences in terms of quality of life and work performance.
Migraine, as defined by the International Headache
Society [1], affects about 18% of women and 6% of men in
the United States [2, 3]. The intensity and duration of
symptoms render many migraine sufferers unable to function
or to perform work and leisure activities [3, 4]. Migraine has
long been recognised as a major cause of work absenteeism
and impaired productivity [5, 6] and productivity losses for
migraine patients have been well documented [7].
No large studies have directly assessed patient satis-
faction related to the treatment of migraine in primary care,
partly because there are no objective endpoints for pain
which is, by its nature, subjective. The classical approaches
are based on two major endpoints: resolution of acute pain
and effects on quality of life.
Traditionally the effects of symptomatic treatments are
assessed by rating pain intensity, attack duration, and the
presence/absence of accompanying symptoms. This infor-
mation is obtained only retrospectively by interviewing the
patient or using a headache diary.
Patient satisfaction with migraine treatment requires the
rapid onset of pain relief, early complete relief, sustained
pain freedom, relief of associated symptoms, consistent
pain relief across attacks, the absence of side effects, a fast
return to normal functioning and reduced disruption of
daily activities [8].
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Acute endpoints in migraine treatment
The advent of triptans, which are highly effective drugs for
migraine treatment, stimulated the introduction of new
endpoints for assessing migraine treatments. These include:
(1) degree of pain relief (PR), (2) pain freedom at 2 h (PF),
(3) sustained pain freedom (SPF = pain free at 2 h plus no
use of rescue medication and no recurrence within 24 h)
and (4) sustained pain freedom associated with no adverse
events (SNAE) [9]. These endpoints allow us to measure
treatment effects at different levels that are increasingly
challenging to achieve. However, the choice of endpoint
needs to reflect outcomes that are realistically achievable in
individual patients, according to their illness profile. Each
of these endpoints will be considered in turn, to examine
their relative strengths and limitations as tools to assist in
the measurement of outcomes relevant to patient expecta-
tions, and ultimately patient satisfaction.
Pain relief at 2 h measures the percentage of patients
whose migraine pain intensity changes from moderate or
severe prior to the start of treatment to mild or no pain after
2 h. However, even though pain relief is a desirable out-
come, PR is an imprecise measurement because it
combines patients who are pain free with those who have
residual mild pain at 2 h.
Pain freedom at 2 h (2-h PF), on the other hand, requires
all patients to be pain free at 2 h after dosing, regardless of
baseline pain, and as such is a more robust outcome
measure. Nevertheless, 2-h PF takes no account of what
happens after 2 h. This is an important issue when com-
paring two treatments because, while both may have a high
2-h PF rate, one may be associated with a greater recur-
rence between 2 and 24 h after dosing. Thus, this outcome
measure is unable to distinguish between treatments for an
attribute which is sought by patients, namely sustained pain
relief.
Sustained pain freedom (SPF) addresses the limitations
of the 2-h PF endpoint, and is now widely regarded as an
outcome that more closely represents patient expectations.
This is because it encompasses 2-h PF, but extends the
requirements such that no rescue medication and no
headache recurrence between 2 and 24 h after dosing are
allowed.
SPF with no adverse events (SNAE) goes a step further,
taking into account tolerability in addition to the efficacy of
treatments.
Pain severity and timing of treatment intake
This issue of pain severity raises another important con-
sideration; timing of treatment intake in relation to the time
of onset of the migraine attack.
Traditionally, patients are instructed to take medication
when their baseline pain has reached moderate-severe
intensity. This is particularly the case in classical clinical
trials because it allows measurement of changes from a
high baseline, which increases the likelihood of distin-
guishing between treatments, notably between active and
placebo interventions. This is relevant because the placebo-
response in migraine patients is usually high [9, 10].
Moreover, outside the clinical trial setting patients often
wait until their headache has reached moderate-severe
intensity before starting treatment. They do this for a
variety of reasons. One study found that most commonly it
was because patients wanted to wait and see if it was really
a migraine attack, or only wanted to take medication if it
was a severe attack [11]. Other reasons patients gave
included concerns about side effects, concerns about drug
effectiveness if it was taken too frequently, and worries
about the risk of becoming dependent on the drug [11].
In contrast, the ‘Act when Mild’ paradigm advocates the
intake of migraine medication before acute pain has
reached moderate-severe intensity and/or as soon as pos-
sible after the onset of symptoms [12]. This paradigm is
supported by a growing body of evidence [12]. In partic-
ular, the Act when Mild (AwM) study with almotriptan
12.5 mg provides the most recent and most robust evidence
that the early intake of medication (i.e. while migraine pain
is still mild, and within 1 h of onset of the migraine attack)
is associated with important benefits compared with
delaying intake until pain has reached moderate-severe
intensity [12]. Table 1 summarises how the AwM study
outcomes address patient expectations of treatment. Com-
pared with delaying intake of medication, taking
almotriptan 12.5 mg early—before the acute attack has
peaked—is more likely to provide outcomes that meet most
of patient expectations.
How do the AwM study endpoints meet patient
expectations?
The limited ability of different endpoints to distinguish
between treatments is illustrated in a recent paper by Fer-
rari and colleagues about a meta-analysis of 53 triptan
studies involving over 24,000 migraine patients (Table 2)
[13]. The endpoints used in this meta-analysis were pain
relief at 2 h, SPF, consistency of effect over more than one
migraine attack, and tolerability. Several features of this
meta-analysis are notable. First, comparisons were made
between sumatriptan 100 mg as the point of reference and
5 other triptans—almotriptan, eletriptan, naratriptan, riza-
triptan, and zolmitriptan. Secondly, a tendency to a dose–
response pattern was apparent for sumatriptan, eletriptan,
and rizatriptan across the different endpoints. The
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outcomes for pain relief and SPF were generally similar for
each individual triptan, suggesting either that there was
consistency across treatments for these endpoints, or that
neither of these endpoints was sensitive enough to distin-
guish differences between the drugs. There were greater
differences between triptans for tolerability, assessed as
adverse events, than for measures of efficacy [13]. This is
an important observation, because ‘absence of side effects’
is a key treatment attribute sought by migraine patients.
Therefore, the composite endpoint of SPF plus no adverse
events (SNAE) has been proposed as a relevant outcome
measure [9]. This is the most challenging endpoint to
achieve because it combines multiple outcome criteria,
namely 2-h PF, plus no use of rescue medication, plus no
recurrence within 24 h of dosing, plus the absence of side
effects.
The SNAE is the most challenging endpoint to achieve
can be seen from a recent analysis of comparative out-
comes of treatment with almotriptan 12.5 mg in triptan-
naive (TrN) versus triptan-experienced (TrE) migraine
patients (Fig. 1) [14]. This was a post hoc analysis in
migraine patients with moderate-severe pain intensity at
the time of treatment, in which the endpoints of 2-h pain
relief, 2-h PF, SFP and SNAE were analysed. The results
indicated that although SNAE is the most challenging
outcome, approximately one-third of patients treated with
almotriptan 12.5 mg achieved it. Moreover, this was the
case whether patients were TrN or TrE, indicating a high
level of benefit from almotriptan regardless of triptan his-
tory. However, this analysis has a limited value due to the
absence of a comparator group.
In order to address this point, we can consider the
influence of SNAE on the outcomes reported in the meta-
analysis of Ferrari and colleagues [13]. Based on SPF and
AE rates calculated for different triptans, eletriptan 20 mg
was associated with the lowest SPF rate (although this is
attributable to the fact that this is now recognised as a sub-
therapeutic dose), and almotriptan 12.5 mg had the highest
SPF rate [9]. Eletriptan 80 mg, a higher-end dose of this
triptan, was associated with the highest incidence of AEs,
and almotriptan 12.5 mg the lowest incidence (Fig. 2).
Expressing these data graphically shows a clear pattern
of a dose–response effect for sumatriptan, eletriptan, riza-
triptan, and zolmitriptan for both SPF and AE (Fig. 2). It is
Table 1 How the AwM study
results meet patient
expectations. Adapted from [12]
a Points 1 and 3 column on the
right show only a trend to
significance, points 4, 7, 9 not
covered in [12] but could be
evidence
b Measured in mild-moderate
pain for almotriptan versus
placebo
Patients-sought attribute of treatment AwM study outcome variables
(still mild vs. moderate-severe)a
1. Complete relief 1. Increased 2 h pain-free status
2. Fast onset of pain relief 2. Shorter duration of migraine attack
3. Rapid restoration of normal functioning 3. Faster achievement of pain-free status
4. Relief of associated symptoms 4. Early pain relief within 0–2 hb
5. No recurrence 5. Reduced duration of migraine pain
6. Absence of side effects 6. Less time lost in daily activities
7. Reduced nausea, vomiting, phono-photo-
and osmophobia
8. Higher sustained pain-free state
9. Less use of rescue medication
10. Placebo-like safety and tolerability
Table 2 Comparison of triptan
outcomes with sumatriptan
100 mg
Derived from a meta-analysis of
53 trials involving 24,089
patients [12]. Data for
frovatriptan unavailable.
Reprinted from Ferrari et al.
(2001) Lancet 358:1668–1675.
With permission
- Inferior to Sumatriptan
100 mg, = equivalent to
Sumatriptan
100 mg, + superior to
Sumatriptan 100 mg
Pain relief at 2 h Sustained pain free Consistency Tolerability
Sumatriptan 25 mg - -/= - +
Sumatriptan 50 mg = = -/= =
Almatriptan 12.5 mg = + + ++
Eletriptan 20 mg - - - =
Eletriptan 40 mg =/+ =/+ = =
Eletriptan 80 mg + + = -
Naratriptan 2.5 mg - - - ++
Rizatriptan 5 mg = = = =
Rizatriptan 10 mg + + ++ =
Zolmitriptan 2.5 mg = = = =
Zolmitriptan 5 mg = = = =
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also clear from this graph that almotriptan 12.5 mg is an
outlier because of its high efficacy combined with its good
tolerability. Statistical analysis and logistic regression
confirmed that higher SPFs were strongly associated with
higher AE rates, with the notable exception of almotriptan
12.5 mg [9]. Using these data, SNAE was calculated for
each triptan dose under the base-case assumption of inde-
pendence between efficacy and tolerability. The highest
SNAE rate was for almotriptan 12.5 mg (22.2%). The
analysis also showed that almotriptan had an 88% proba-
bility of being superior to sumatriptan 100 mg in terms of
SNAE across all values for the efficacy–tolerability rela-
tionship for these triptans. The SNAE therefore not only
incorporates treatment attributes that are relevant to patient
satisfaction, but is also a useful measure for discriminating
between migraine therapies.
Other endpoint measures and migraine assessments
As well as the use of ‘traditional’ endpoints to assess
outcomes of migraine treatment, a number of other issues
need to be considered in order to provide a broader picture
of patient progress.
Headache-related disability associated with migraine is
poorly recognised in clinical practice, often leading to the
use of ineffective care strategies, and an apparently poor
outcome. Evaluation of the level of migraine-related dis-
ability is crucial to enable effective treatment decisions to
be made; for example, between stepped care versus strat-
ified care, as described by Diener et al. [15].
As migraine is a chronic illness, recurrent attacks can
have a negative impact on health-related QOL (HRQOL)
because each attack, as well as the anticipation of an attack,
can interfere with a migraineur’s ability to work, enjoy
daily activities and interact socially. Therefore, measure-
ment of HRQOL in migraine patients is needed to provide
a more complete picture of the progress of the patient
beyond the clinical symptoms associated with migraine.
Medication-overuse headache (MOH) can develop from
frequent, and sometimes excessive, use of pain medica-
tions. It is important, then, that with the availability of a
variety of migraine medications, both over-the-counter and
on prescription, a record of medication use is kept. This can
help identify or discount MOH as a contributory factor to
headache recurrence in migraineurs, which is important as
otherwise MOH may limit optimal outcomes.
Lastly, Kaplan–Meier plots, sometimes called survival
curves, can be used as a graphically visual display of pain
outcomes in migraineurs that can be relevant when evalu-
ating different interventions.
These measures will be considered in more detail.
Disability
The Migraine Disability Assessment (MIDAS) Question-
naire was developed to assist rational treatment decisions
and evaluate progress [16]. Migraine sufferers answer five
questions that assess time lost in days due to headaches in
three domains covering the previous 3-month period. The
three domains include employment (paid work or school),
household work, and family/social/leisure activities. The
MIDAS score is the sum of the answers to the five ques-
tions. Another two questions (A & B) are not scored but
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Fig. 1 Almotriptan in triptan-naive versus experienced patients
(treated with almotriptan 12.5 mg) after Pascual et al. [14] with
permission. 2-h PR pain relief at 2 h, 2-h PF pain-free at 2 h, 2-h SPF
sustained pain-freeat 2–24 h without rescue medication, SNAE
sustained pain-free and no AEs, Recur headache recurrence at 24 h,
Rescue rescue medication 2–24 h,AE adverse event
Fig. 2 SPF versus adverse event rates for different triptans. Derived
from a meta-analysis of 53 trials involving 24,089 patients [9]. Data
for frovatriptan unavailable. After Dodick et al. (2007) CNS Drugs 21
(1):73–82 with permission. A Almotriptan, E eletriptan, N naratriptan,
R rizatriptan, Z zolmitriptan
210 J Headache Pain (2008) 9:207–213
123
provide the physician with clinically relevant information
on attack frequency and pain severity.
Its ease, simplicity, high consistency and reliability
support the use of the MIDAS Questionnaire in everyday
clinical practice. The MIDAS grades provide an intuitive
means of representing headache-related disability. MIDAS
is an effective tool to improve communication between
patients and healthcare professionals. As it assesses head-
ache-related disability and provides information on
headache frequency and pain intensity, it can be used to
increase awareness of, and highlight problems associated
with, migraine. MIDAS can be used as a screening tool to
help physicians provide appropriate treatment at the
patient’s initial consultation based on level of disability.
Patients who present with a high MIDAS score may require
referral to specialist physicians for a more detailed
diagnosis.
The change in MIDAS score during treatment can also
be used to monitor therapeutic response to treatment and
patient progress over time. MIDAS can be used to support
public health initiatives, such as evaluating the true extent
and costs of migraine, which may be underestimated by
healthcare professionals and payers.
HRQOL
The use of HRQOL as an endpoint measure of migraine
treatment is based on the presence of a wealth of literature
describing the effect of the chronic nature of migraine on
HRQOL [17, 18]. Its high burden has been likened to that
of osteoarthritis and diabetes mellitus, and the high prev-
alence of migraine adds to the socioeconomic burden [17,
18].
Two types of questionnaire have been used to measure
HRQOL: general and disease-specific instruments. General
QOL scales assess a number of activities within physical,
social, psychological and behavioural life domains. Dis-
ease-specific instruments reflect particular limitations or
restrictions associated with specific disease states [9] and
can evaluate changes over time. There are three main
instruments: migraine diaries, migraine-specific HRQOL
instruments and the Short Form Health Survey (SF-36).
With the migraine diary one can rate headache severity
(none, mild, moderate, severe) functional disability (none,
mild, severe, bed rest) and associated symptoms (nausea,
vomiting, photo/phonophobia). Paper and electronic diaries
are available [19].
Migraine-specific HRQOL (MS-HRQOL) instruments
are available to evaluate changes over time in work and
social functioning, energy/vitality, symptoms and feelings/
concerns. While these outcomes are not acute symptom-
specific, they measure the effect on QOL of changes in
symptoms across multiple attacks over time, and so enable
a longer term perspective of the wider effects of a treat-
ment paradigm to be assessed [20, 21].
The Short-Form Health Survey (SF-36) is a general
health survey questionnaire (i.e. not migraine-specific)
consisting of eight domains, each scored from 0 (worst
possible outcome) to 100 best possible outcome [22].
Completion of the SF-36 at specified intervals throughout
the course of the migraine illness can monitor changes in
QOL over time and so identify areas that may require
closer clinical attention that would not be identified using
traditional acute symptomatic endpoints [10].
However, just how sensitive these QOL instruments are
at detecting clinically significant changes over time is not
entirely clear and, although these instruments are useful
endpoints for migraine clinical trials, their role in clinical
practice is yet to be established [12].
Medication-overuse headache
Another issue that can influence endpoints in migraine
treatment is MOH [1]. The 2004 International Headache
Society criteria guidelines state that MOH can be associ-
ated with the use of simple analgesics (aspirin or
paracetamol), combination analgesics (containing caffeine,
codeine or barbiturates), opioids, ergotamine or triptans, if
taken for more than 10 days (15 days for simple analge-
sics) in more than 3 months.
Medication-overuse headache is currently a ‘hot topic’
in migraine treatment, not least because several issues
associated with MOH can have an impact on migraine
treatment endpoints. There is current ongoing debate about
whether medication overuse is a cause or a consequence of
chronic daily headache. The incidence and prevalence of
MOH is not clear, because the definitions of MOH have,
until recently, been unclear. Moreover, physician–patient
communication is not always at a level that identifies this
issue, since a diagnosis of MOH can only be made after the
patient has stopped taking the medication. Susceptible
individuals have a pre-existing episodic headache condi-
tion (most frequently migraine or tension-type headache)
and the frequent (maybe daily) use of the analgesics
referred to earlier ‘transforms’ the headache into one that
occurs daily.
The characteristics of MOH include an increased fre-
quency of headaches over time (without the patient being
aware), waking with a headache in the morning which was
not a feature of the original headache type, headache
lacking features specific to migraine or tension-type
headache, and headache occurring more easily after stress
or exertion so that greater doses of medication are required
to alleviate the headache. In addition, headaches recur
within a predictable period after the last dose of medica-
tion, usually with reduced efficacy.
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The goals of management in MOH are to identify any
comorbid conditions driving the MOH, educate the patient,
withdraw daily treatment (to restore an episodic headache
pattern), and (re)establish an effective treatment strategy
with acute and preventative medications [23–25].
Displaying endpoints
Finally, differing methods of displaying study endpoints
can provide different views of the results. The data on
duration of migraine attack presented by de Klippel for the
AwM study provide an example [11]. Using a traditional
bar chart, the mean duration was significantly shorter if
almotriptan was taken when pain was still mild and within
1 h of pain onset compared with delaying treatment until
pain was moderate-severe (2 vs. 5 h, P \ 0.0005)
(Fig. 3a).
However, displaying the results in this way tells us
nothing about the evolution of differences over time. In
contrast, if the results are displayed as a Kaplan–Meier plot
(Fig. 3b), this alternative visual display enables us to see
the evolution of the differences over time, which empha-
sises the benefits of the early intervention in migraine.
Conclusion
Traditional acute endpoints that evaluate migraine treat-
ment need to be selected to best reflect individual patient
expectations. Of these endpoints, SNAE appears to be the
most challenging but also the most discriminating. To
provide a complete picture, additional endpoints need to be
taken into account. For example, the impact of migraine-
related disability (e.g. MIDAS), the effect on HRQOL (e.g.
MS-HRQOL, SF-36), and the risk and consequences of
medication overuse should be considered. In addition,
consideration should be given to the visual impact of
endpoint displays; an appropriate figure can provide an
intuitively simple overview of progress. For example,
Kaplan–Meier plots can visually differentiate between
interventions over time. In the future, a composite endpoint
of pain resolution and QOL restoration would constitute a
step forward in migraine management.
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